Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Carcinoma, Small Cell 1Breast Neoplasms 1

Interventions

Carboplatin 15Etoposide 13atezolizumab 9Topotecan 8durvalumab 7Specimen Handling 7PM 01183 6Cisplatin 5pembrolizumab 4Magnetic Resonance Spectroscopy 4Irinotecan 4Injections 3Biopsy 3berzosertib 2Nivolumab 2Fulvestrant 2Drug Therapy 2AMG 757 2tremelimumab 1trastuzumab deruxtecan 1toripalimab 1tazemetostat 1palbociclib 1olaparib 1lenvatinib 1fludarabine 1enzalutamide 1cabozantinib 1budigalimab 1arginine decarboxylase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × EC regimen × 30 days × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡